ENYO Pharma Announces 16 Weeks Vonafexor (EYP001) Top-Line Interim Results from Two on-going Phase 2a Studies in Chronic Hepatitis B Patients

Published on 30/07/2021

Lyon, France. July 30, 2021 – ENYO Pharma (ENYO), a private clinical stage biotechnology company developing innovative drug candidates, today announced positive proof of concept data from Study EYP001-203 of Vonafexor in combination with pegylated-Interferon (peg-IFN) in viremic patients with chronic hepatitis B (CHB).

Read next in 'Press releases'

• ENYO Pharma announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
• ENYO Pharma annonce l’obtention des résultats finaux de l’étude clinique de Phase 2 ALPESTRIA‑1 dans le syndrome d’Alport, confirmant la capacité du vonafexor à inverser la trajectoire du déclin rénal et à démontrer un effet thérapeutique durable
• ENYO Pharma annonce la finalisation de son financement de série C avec Vesalius Biocapital et la poursuite de son étude clinique de phase 2 ALPESTRIA-1
• ENYO Pharma announces completion of Series C financing with Vesalius Biocapital and continued progress of its ALPESTRIA-1 clinical Phase 2 study in Alport syndrome patients
• ENYO Pharma announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome